|
1
|
Colston KW, Lowe LC, Mansi JL and Campbell
MJ: Vitamin D status and breast cancer risk. Anticancer Res.
26:2573–2580. 2006.PubMed/NCBI
|
|
2
|
Harirchi I, Kolahdoozan S, Karbakhsh M,
Chegini N, Mohseni SM, Montazeri A, Momtahen AJ, Kashefi A and
Ebrahimi M: Twenty years of breast cancer in Iran: Downstaging
without a formal screening program. Ann Oncol. 22:93–97. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
McCarthy K, Laban C, Bustin SA, Ogunkolade
W, Khalaf S, Carpenter R and Jenkins PJ: Expression of
25-hydroxyvitamin D-1-alpha-hydroxylase and Vitamin D receptor mRNA
in normal and malignant breast tissue. Anticancer Res. 29:155–157.
2009.PubMed/NCBI
|
|
4
|
Haussler MR, Whitfield GK, Kaneko I,
Haussler CA, Hsieh D, Hsieh JC and Jurutka PW: Molecular mechanisms
of vitamin D action. Calcif Tissue Int. 92:77–98. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Anderson MG, Nakane M, Ruan X, Kroeger PE
and Wu-Wong JR: Expression of VDR and CYP24A1 mRNA in human tumors.
Cancer Chemother Pharmacol. 57:234–240. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ordonez-Moran P, Larriba MJ, Pendas-Franco
N, Aguilera O, Gonzalez-Sancho JM and Munoz A: Vitamin D and
cancer: An update of in vitro and in vivo data. Front Biosci.
10:2723–2749. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Segersten U, Holm PK, Björklund P, Hessman
O, Nordgren H, Binderup L, Akerström G and Hellman P:
25-Hydroxyvitamin D3 1alpha-hydroxylase expression in breast cancer
and use of non-1alpha-hydroxylated vitamin D analogue. Breast
Cancer Res. 7:R980–R986. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang J and Jiang YF: Natural compounds as
anticancer agents: Experimental evidence. World J Exp Med. 2:45–57.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Luo W, Hershberger PA, Trump DL and
Johnson CS: 24-Hydroxylase in cancer: Impact on vitamin D-based
anticancer therapeutics. J Steroid Biochem Mol Biol. 136:252–257.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Horváth HC, Lakatos P, Kósa JP, Bácsi K,
Borka K, Bises G, Nittke T, Hershberger PA, Speer G and Kállay E:
The candidate oncogene CYP24A1: A potential biomarker for
colorectal tumorigenesis. J Histochem Cytochem. 58:277–285. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chun RF, Liu PT, Modlin RL, Adams JS and
Hewison M: Impact of vitamin D on immune function: Lessons learned
from genome-wide analysis. Front Physiol. 5:1512014.PubMed/NCBI
|
|
12
|
Townsend K, Banwell CM, Guy M, Colston KW,
Mansi JL, Stewart PM, Campbell MJ and Hewison M: Autocrine
metabolism of vitamin D in normal and malignant breast tissue. Clin
Cancer Res. 11:3579–3586. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Anderson PH, O'Loughlin PD, May BK and
Morris HA: Quantification of mRNA for the vitamin D metabolizing
enzymes CYP27B1 and CYP24 and vitamin D receptor in kidney using
real-time reverse transcriptase-polymerase chain reaction. J Mol
Endocrinol. 31:123–132. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Garland CF, Garland FC, Gorham ED, Lipkin
M, Newmark H, Mohr SB and Holick MF: The role of vitamin D in
cancer prevention. Am J Public Health. 96:252–261. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Aung TT, Chandana SR, D'Silva KJ and
Dimitrov NV: The role of vitamin D in breast cancer. Oncol Rev.
3:19–25. 2009. View Article : Google Scholar
|
|
16
|
Friedrich M, Diesing D, Cordes T, Fischer
D, Becker S, Chen TC, Flanagan JN, Tangpricha V, Gherson I, Holick
MF and Reichrath J: Analysis of 25-hydroxyvitamin
D3-1alpha-hydroxylase in normal and malignant breast tissue.
Anticancer Res. 26:2615–2620. 2006.PubMed/NCBI
|
|
17
|
Fischer D, Becker S, Cordes T, Bücker B,
Diedrich K, Friedrich M, Salehin D and Thill M: Vitamin
D-24-hydroxylase in benign and malignant breast tissue and cell
lines. Anticancer Res. 29:3641–3645. 2009.PubMed/NCBI
|
|
18
|
Lowe LC, Guy M, Mansi JL, Peckitt C, Bliss
J, Wilson RG and Colston KW: Plasma 25-hydroxy vitamin D
concentrations, vitamin D receptor genotype and breast cancer risk
in a UK Caucasian population. Eur J Cancer. 41:1164–1169. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Evans SR, Nolla J, Hanfelt J, Shabahang M,
Nauta RJ and Shchepotin IB: Vitamin D receptor expression as a
predictive marker of biological behavior in human colorectal
cancer. Clin Cancer Res. 4:1591–1595. 1998.PubMed/NCBI
|
|
21
|
Fischer D, Thomé M, Becker S, Cordes T,
Diedrich K, Friedrich M and Thill M: 25-Hydroxyvitamin D3
1alpha-hydroxylase splice variants in benign and malignant ovarian
cell lines and tissue. Anticancer Res. 29:3627–3633.
2009.PubMed/NCBI
|
|
22
|
Fleet JC, DeSmet M, Johnson R and Li Y:
Vitamin D and cancer: A review of molecular mechanisms. Biochem J.
441:61–76. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Welsh JE: Vitamin D metabolism in mammary
gland and breast cancer. Mol Cell Endocrinol. 347:55–60. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Thill M, Hoellen F, Becker S, Dittimer C,
Fischer D, Kümmel S, Salehin D, Friedrich M, Köster F, Diedrich K
and Cordes T: Expression of prostaglandin- and vitamin
D-metabolising enzymes in benign and malignant breast cells.
Anticancer Res. 32:367–372. 2012.PubMed/NCBI
|
|
25
|
Ren S, Nguyen L, Wu S, Encinas C, Adams JS
and Hewison M: Alternative splicing of vitamin D-24-hydroxylase: A
novel mechanism for the regulation of extrarenal
1,25-dihydroxyvitamin D synthesis. J Biol Chem. 280:20604–20611.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mimori K, Tanaka Y, Yoshinaga K, Masuda T,
Yamashita K, Okamoto M, Inoue H and Mori M: Clinical significance
of the overexpression of the candidate oncogene CYP24 in esophageal
cancer. Ann Oncol. 15:236–241. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tanner MM, Grenman S, Koul A, Johannsson
O, Meltzer P, Pejovic T, Borg A and Isola JJ: Frequent
amplification of chromosomal region 20q12-q13 in ovarian cancer.
Clin Cancer Res. 6:1833–1839. 2000.PubMed/NCBI
|
|
28
|
Albertson DG, Ylstra B, Segraves R,
Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW and Pinkel D:
Quantitative mapping of amplicon structure by array CGH identifies
CYP24 as a candidate oncogene. Nat Genet. 25:144–146. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lopes N, Sousa B, Martins D, Gomes M,
Vieira D, Veronese LA, Milanezi F, Paredes J, Costa JL and Schmitt
F: Alterations in Vitamin D signalling and metabolic pathways in
breast cancer progression: A study of VDR, CYP27B1 and CYP24A1
expression in benign and malignant breast lesions. BMC Cancer.
10:4832010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Grant WB: The likely role of vitamin D
from solar ultraviolet-B irradiance in increasing cancer survival.
Anticancer Res. 26:2605–2614. 2006.PubMed/NCBI
|
|
31
|
Bacchetta J, Sea JL, Chun RF, Lisse TS,
Wesseling-Perry K, Gales B, Adams JS, Salusky IB and Hewison M:
Fibroblast growth factor 23 inhibits extrarenal synthesis of
1,25-dihydroxyvitamin D in human monocytes. J Bone Miner Res.
28:46–55. 2013. View Article : Google Scholar : PubMed/NCBI
|
